Charles River's $470m Frontage Carve-Out Buys Bioanalysis Depth Through a Take-Private
Charles River will pay about $470m, plus up to $75m in performance payments, for Frontage's Exton bioanalysis and DMPK units. The deal needs a consortium to take the parent private first.
What happened
Charles River Laboratories has signed definitive agreements to acquire Frontage's bioanalysis and drug metabolism and pharmacokinetics (DMPK) businesses in Exton, Pennsylvania, for about $470m. Up to $75m in further performance-based payments could follow. The structure is unusual: the transaction runs through a consortium arrangement that first takes Frontage private, so the Exton units reach Charles River only after the parent changes hands.
The material available does not specify the consortium's members, the closing timetable, or the financial profile of the Exton units. Those are the first things to establish. The headline price and the earn-out are the only hard numbers, and the earn-out matters for what it signals, covered below.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Charles River to acquire Frontage's Exton bioanalysis and DMPK businesses for about $470m Charles River Laboratories International, Inc. · 09 Nov 2026
- MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first Macrogenics Inc · 13 Nov 2026
- Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient Xenetic Biosciences, Inc. · 13 Nov 2026
- Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review Longeveron Inc. · 12 Nov 2026
- Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage Silence Therapeutics plc · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.